摘要
背景:美国国家任务组(NTG)为唐氏综合症患者痴呆筛查(DS)和其他形式的身份(非DS)者提倡改编版的痴呆筛查问卷为智障人士使用(dsqiid)。 目的:为了满足这些准则,研究表明在一个由40岁以上的DS和DS ID非成年人意大利版的心理测量学特性。 方法:内部一致性、跨评估者和评估者内信度、结构效度、会聚效度和已知组差异与招募200个来自意大利市15个中心的老年痴呆患者(ID评估(55.2年;平均范围40-80岁)。老年痴呆症的诊断是根据IASSID诊断标准和临床确定度做的西尔弗曼等人定义的分类(2004)。 结果:克龙巴赫的阿尔法的dsqiid-i 0.94。ICC为评分者间信度和重测信度为0.89。主成分分析显示三个领域,即记忆和混乱相关的项目,运动和功能残疾,抑郁和冷漠,这解释了几乎40%的整体方差。总dsqiid-i评分显著相关,不同个体显著的DMR(n = 34)与认知功能下降无(N = 166)。年龄、性别和身份的dsqiid-i.严重程度无关 结论:本研究证实了,文化的价值dsqiid这是一种心理测量学的有效的和用户友好的观察员的规模与DS和DS ID非成人痴呆筛查。
关键词: 阿尔茨海默病(AD),痴呆,智力残疾,心理测量学,筛查试验,验证。
Current Alzheimer Research
Title:A Multicentre Italian Validation Study in Aging Adults with Down Syndrome and Other Forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities
Volume: 14 Issue: 7
关键词: 阿尔茨海默病(AD),痴呆,智力残疾,心理测量学,筛查试验,验证。
摘要: Background: The USA National Task Group (NTG) guidelines advocate the use of an adapted version of Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) for dementia screening of individuals with Down syndrome (DS) and with other forms of ID (non-DS).
Objective: In order to meet these guidelines, this study verifies the psychometric properties of an Italian version of the original DSQIID in a population composed of adults aged 40 years and over with DS and non-DS ID. Methods: Internal consistency, inter-rater and intra-rater reliabilities, structural validity, convergent validity and known group differences of DSQIID-I were assessed with 200 individuals with ID (mean of 55.2 years; range: 40-80 years) recruited from 15 different centers in Italy. Diagnosis of dementia was done according to IASSID diagnostic criteria and its degree of clinical certainty was defined according to Silverman et al.’s classification (2004). Results: Cronbach’s alpha for the DSQIID-I was 0.94. The ICCs for inter-rater and test-retest reliability were both 0.89. A Principal Component analysis revealed three domains, namely memory and confusion- related items, motor and functional disabilities, depression and apathy, which explained almost 40% of the overall variance. The total DSQIID-I score correlated significantly with DMR and differed significantly among those individuals (n = 34) with cognitive decline from those without (n = 166). Age, gender and severity of ID were unrelated to the DSQIID-I. Conclusion: The present study confirms the cross-cultural value of DSQIID which was proved to be a psychometrically valid and user-friendly observer-rated scale for dementia screening in adults with both DS and non-DS ID.Export Options
About this article
Cite this article as:
A Multicentre Italian Validation Study in Aging Adults with Down Syndrome and Other Forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities, Current Alzheimer Research 2017; 14 (7) . https://dx.doi.org/10.2174/1567205014666170117094757
DOI https://dx.doi.org/10.2174/1567205014666170117094757 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
CNS & Neurological Disorders - Drug Targets A Review: Natural Compounds as Anti-Alzheimer´s Disease Agents
Current Nutrition & Food Science The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Prion Function and Pathophysiology in Non-Mammalian Models
Current Molecular Medicine Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: The Crosstalk between Non-Pharmaceutical and Pharmaceutical Approaches to Prevention and Treatment of Chronic Diseases: Current Concepts and Perspectives)
Current Pharmaceutical Design Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Oral Lipid Based Drug Delivery System (LBDDS): Formulation, Characterization and Application: A Review
Current Drug Delivery Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders
Current Neuropharmacology Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research Editorial: In Silico Methodologies Applied to Drug Discovery
Combinatorial Chemistry & High Throughput Screening Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Advances in Drug Safety
Current Pharmaceutical Design Human Disease and Drug Pharmacology, Complex as Real Life
Current Medicinal Chemistry Disturbed Sleep Patterns in Elders with Mild Cognitive Impairment: The Role of Memory Decline and ApoE ε 4 Genotype
Current Alzheimer Research